News & Events
Crinetics' Second Quarter 2021 Financial Results and Corporate Update
“We’ve seen advancements across our pipeline over the past months, with the commencement of dosing in the Phase 3 PATHFNDR-1 trial of paltusotine in acromegaly and the announcement of data from CRN04894’s Phase 1 program,” said Scott Struthers, Ph. D. , Founder and Chief Executive Officer of Crinetics.
READ MORECRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study
Crinetics ($CRNX) today announced positive interim findings from the single ascending dose (SAD) arm of a first-in-human study with CRN04894 demonstrating pharmacologic proof-of-concept for this first-in-class oral, nonpeptide adrenocorticotropic hormone (ACTH) antagonist that is being developed for the treatment of conditions of ACTH excess, including Cushing’s disease and congenital adrenal hyperplasia.
READ MORECrinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the
READ MORECrinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a wide cross section of acromegaly patients.
READ MORECrinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
Garlan Adams brings over two decades of experience managing legal and compliance matters associated with the development and commercialization of innovative pharmaceutical and biotechnology products.
READ MOREFirst Quarter 2021 Financial Results and Corporate Update
“In the first quarter we achieved key clinical and regulatory milestones across our pipeline,” said Scott Struthers, Ph. D. , Founder and Chief Executive Officer of Crinetics.
READ MORECrinetics Announces Closing of Common Stock Offering
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock.
READ MORECrinetics Announces Pricing of Common Stock Offering
Paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
